Reata Pharmaceuticals, Inc.
(NASDAQ : RETA)

( )
RETA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.21%149.480.7%$741.20m
BMYBristol-Myers Squibb Co. 1.06%67.431.0%$732.45m
PFEPfizer Inc. -0.40%40.350.9%$572.52m
MRKMerck & Co., Inc. -1.11%89.960.7%$567.99m
ABBVAbbVie, Inc. 0.00%88.002.3%$549.02m
LLYEli Lilly & Co. 0.96%140.921.1%$394.62m
APLSApellis Pharmaceuticals, Inc. 6.27%43.040.0%$117.42m
NVSNovartis AG -0.78%95.190.2%$109.87m
AZNAstraZeneca Plc -1.04%50.801.2%$95.45m
GSKGlaxoSmithKline Plc -0.81%47.500.2%$89.73m
KRTXKaruna Therapeutics, Inc. 4.57%109.300.0%$65.08m
NVONovo Nordisk A/S -0.26%61.150.1%$64.59m
RETAReata Pharmaceuticals, Inc. 0.71%212.933.5%$64.21m
SNYSanofi -2.01%50.210.2%$58.92m
RARXRa Pharmaceuticals, Inc. -0.23%46.860.8%$36.84m

Company Profile

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.